KATHERINE KWONG: Open Payments
NPI 1508240375 · SANTA CLARA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,260 in 10 payments from 10 companies in 2025. Trend: 2023 $330 · 2024 $1,249 · 2025 $1,260
Food & beverage: $1,260
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 1 | $145 |
| Galderma Laboratories, L.P. | 1 | $140 |
| Edwards Lifesciences Corporation | 1 | $137 |
| Neurelis, Inc. | 1 | $134 |
| Gilead Sciences, Inc. | 1 | $127 |
| Madrigal Pharmaceuticals | 1 | $125 |
| Lilly USA, LLC | 1 | $117 |
| ARGENX US, INC. | 1 | $115 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $112 |
| Janssen Pharmaceuticals, Inc | 1 | $109 |
Products named: DEXCOM G7 GSS (161), NEMLUVIO, SAPIEN 3 Ultra RESILIA, VALTOCO, REZDIFFRA, KISUNLA, VYVGART, SPRAVATO.
Industry payments across CA — which companies pay providers there.
